The author's response

Lloyd Kelland

Cancer Research Technology Development Laboratories, Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK. e-mail: lkelland@cantertechnology.com

I think that the comments made by [Guido Cavaletti](#) relating to my [Review](#) are reasonable, although a brief mention of neurotoxicity was included in the article, particularly with reference to oxaliplatin and cisplatin itself. It also might be noted that, despite the comment, the major driving forces for new platinum-drug development over the years have been lessening the nephrotoxicity of cisplatin (achieved with carboplatin) and/or overcoming tumour resistance. This is exemplified by the fact that oxaliplatin was approved to broaden the therapeutic usefulness of the platins into patients with colorectal cancer, despite the peripheral neuropathy reported with this drug in early clinical trials.